Serum IL-6 and TNF-α in Type 1 Diabetes Mellitus Patients in Mosul
AbstractThe objective of the study is to evaluate the levels of IL-6 and TNF-α in sera of patients with type 1 diabetes mellitus (T1DM) compared to healthy people and correlate their levels with different factors. The results showed significant increase in the levels of IL-6 and TNF-α (P≤0.05) in T1DM compared to control group. The levels of IL-6 were not significant when compared with age groups, duration of the disease and level of HbA1c. On contrast the levels of TNF-α in T1DM patients was significantly increased (P≤0.05) when compared with age groups and duration of the disease but not significantly with different HbA1c.
Ferreira-Hermosillo A, Molina-Ayala M , Ramírez-Rentería C , Vargas G1, Gonzalez B, Isibasi A , et al.. Inflammatory Cytokine Profile Associated with Metabolic Syndrome in Adult Patients with Type 1 Diabetes. J Diabetes Res. 2015;2015:972073.
Alnek K, Kisand K, Heilman K, Peet A, Varik K, Uibo R (2015) Increased Blood Levels of Growth Factors, Proinflammatory Cytokines, and Th17 Cytokines in Patients with Newly Diagnosed Type 1 Diabetes. PLoS ONE 10(12): e0142976.
International Diabetic Federation. IDF diabetes atlas 7th ed. Brussels: International Diabetic Federation; 2015.
Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller D A, et al.. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest. 1994 May; 93(5): 1968–1974.
Peraldi P, Spiegelman B. TNF-α and insulin resistance: Summary and future prospects. Molecular and Cellular Biochemistry, 1998, 182(1-2): 169-175.
Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. 1999;353(9165):1649-1652.
Erbağci AB, Tarakçioğlu M, Coşkun Y, Sivasli E, Namiduru ES. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clinical Biochemistry 2001;34(8):645-650.
Ozer G, Teker Z, Cetiner S, Yilmaz M, Topaloglu AK, Onenli-Mungan N, et al. Serum IL-1, IL-2, TNFalpha and INFgamma levels of patients with type 1 diabetes mellitus and their siblings. Journal of Pediatric Endocrinology and Metabolism 2003;16(2):203-210.
Davì G, , Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, et al. Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus: Role of Interleukin-6 and Disease Duration . Circulation 2003;107(25):3199-3203.
Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes. 2004;53(7):1643-1648.
Pal M, Febbraio MA, Whitham M. From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation. Immunol Cell Biol. 2014 ;92(4):331-339.
Glund S, Deshmukh A, Long YC, Moller T, Koistinen HA, et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes. 2007;56(6):1630-1637.
Nieto-Vazquez I, Fernández-Veledo S, de Alvaro C, Lorenzo M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes. 2008;57(12):3211-3221.
Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17(11):1481-1489.
Suzuki T, Imai J, Yamada T, Ishigaki Y, Kaneko K, Uno K, et al. Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway. Diabetes. 201;60(2):537-547.
Karavanaki K1, Kakleas K, Georga S, Bartzeliotou A, Mavropoulos G, Tsouvalas M, et al. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis. Clin Biochem. 2012;45(16-17):1383-1388.
Chen YL, Qiao YC2, Pan YH, Xu Y, Huang YC, Wang YH1, Geng LJ, et al. Correlation between serum interleukin-6 level and type 1 diabetes mellitus: A systematic review and meta-analysis. Cytokine. 2017;94:14-20.
Huang W, Wang DS, Li XY, Wu WZ,Ni GC. Expression of levels of IL-6 mRNA in PBMNCs from patients with IDDM and normal by RT-PCR procedure. Clin Chinese Med J. 1993;106(12):893-897.
Kulseng B, Skjåk-Braek G, Følling I, Espevik T. TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide. Scand J Immunol. 1996;43(3):335-340.
Geerlings SE, Brouwer EC, Van Kessel KC, Gaastra W, Stolk RP, Hoepelman AI. Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest. 2000;30(11):995-1001.
Hammed IK, Rashid NF, Abed NA. Serum interleukin-6 level in children with type 1 diabetes mellitus. J Fac Med Baghdad. 2012;54(3):228-230.
Kavitha G, Ramani G, Priya KD, Aruna RM. Oxidative stress, IL-6 and atherogenic index of plasma in diabetic nephropathy. J Appl Biol Pharm Technol . 2011;2(2)211-217.
Foss-Freitas MC, Foss NT, Donadi EA, Foss MC. Effect of the glycemic control on intracellular cytokine production from peripheral blood mononuclear cells of type 1 and type 2 diabetic patients. Diabetes Research and Clinical Practice 2008; 82,(3):329–334.
Qiao YC, Chen YL, Pan YH, Tian F, Xu Y, Zhang XX, et al. The change of serum tumor necrosis factor alpha in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. PLoS One. 2017;12(4):e0176157.
Zier KS, Leo MM, Spielman RS, Baker L. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes. 1984;33(6):552-5.
Netea MG, Hancu N, Blok WL, Grigorescu-Sido P, Popa L, Popa V, et al. Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals. Cytokine. 1997 Apr;9(4):284-287.
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.